Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

SX-682 is under clinical development by Syntrix Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

CKD-510 is under development for the treatment of Charcot-Marie-Tooth disease and atrial fibrillation. It is administered through oral route.The drug candidate is a new chemical entity targeting ...

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Metastatic Colorectal Cancer.

Selenium sulfide is under clinical development by Azura Ophthalmics and currently in Phase II for Unspecified Ophthalmological Disorders.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

Dactolisib tosylate is under clinical development by Adicet Bio and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

NVP-1805R2 is under clinical development by NVP Healthcare and currently in Phase I for Unspecified Cardiovascular Disorders.

VTP-500 is under clinical development by Barinthus Biotherapeutics and currently in Phase I for Middle East Respiratory Syndrome (MERS).

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Solid Tumor.